|
|

|
|
Investor Relations :: Directors
& Management Team
|
Management Team
Deirdre Y. Gillespie, M.D.
President and Chief Executive Officer
Gail A. Sloan, CPA
Vice President of Finance and Secretary
|
|

|
|
Board of Directors
Craig R. Smith, M.D.
Robert A. Fildes, Ph.D.
Deirdre Y. Gillespie, M.D.
Stephen M. Martin
Frank E. Young, M.D., Ph.D.
|
|
Management
Team:
|
Deirdre Y. Gillespie, M.D.
President and Chief Executive Officer
|
| |
Deirdre Y. Gillespie, M.D., President, Chief Executive
Officer and Assistant Secretary, joined us in March 2006 as a director,
and as President and Chief Executive Officer. She was appointed Assistant
Secretary in February 2007. Dr. Gillespie previously served as the
President and Chief Executive Officer of Oxxon Therapeutics, Inc., a privately
held pharmaceutical company, from 2001 to 2005. Prior to that, she served as
Chief Operating Officer of Vical, Inc., from 2000 to 2001, and Executive Vice
President & Chief Business Officer, from 1998 to 2000. Dr. Gillespie
also held a number of positions at DuPont Merck Pharmaceutical Company,
including Vice President of Marketing, from 1991 to 1996. Dr. Gillespie
received her M.B.A. from the London Business School and her M.D. and B.Sc. from London University.

|
|
Gail A. Sloan, CPA
Vice President of Finance and Secretary
|
| |
Gail A. Sloan, CPA, Vice President of Finance and Secretary,
joined us in 1996 as Assistant Controller, was promoted to Controller in 1997,
to Senior Director of Finance in 2002 and to Vice President of Finance in 2004.
She was appointed Secretary in 1999. Prior to joining us, from 1993 to 1996,
Ms. Sloan served as Assistant Controller at Affymax Research Institute, a
publicly held drug-discovery research company and formerly a part of the Glaxo
Wellcome Group. From 1985 to 1993, she progressed to the position of Audit
Manager with Ernst & Young LLP. Ms. Sloan holds a B.S. in Business
Administration from California Polytechnic State University, San Luis Obispo
and is a Certified Public Accountant.

|
Board of Directors:
|
Craig R. Smith, M.D.
Chairman of the Board and President of Williston Consulting
|
| |
Craig R. Smith, M.D. has been a director since 2004 and Chairman of
the Board since 2006. Dr. Smith is currently Executive Vice President, Chief
Operating Officer and director of Algenol Biofuels Inc., a privately held
industrial biotechnology company, and the President of Williston Consulting,
LLC, a consulting firm providing advisory services to pharmaceutical and
biotechnology companies. From 1993 to 2004, Dr. Smith served as Chairman,
President and Chief Executive Officer of Guilford Pharmaceuticals, Inc., a
publicly held pharmaceutical company. From 1988 to 1992, Dr. Smith was Vice
President of Clinical Research and from 1992 to 1993, Senior Vice President of
Business and Market Development at Centocor, Inc., a publicly held
biotechnology company, which is now a wholly-owned subsidiary of Johnson &
Johnson. From 1975 to 1988, he served on the faculty of the Department of
Medicine at the Johns Hopkins University School of Medicine. Dr. Smith is
a member of the Johns Hopkins Alliance for Science and a member of the board of
directors of Adams Express Company, a publicly held closed-end equity
investment company, Petroleum & Resources Corporation, a publicly held
equity investment company specializing in energy and natural resources, and
Depomed, Inc., a publicly held specialty pharmaceutical company. Dr. Smith
holds an M.D. from the State University of New York at Buffalo and trained in
Internal Medicine at the Johns Hopkins Hospital from 1972 to 1975.

|
|
Robert A. Fildes, Ph.D.
President, SB2, Inc.
|
| |
Robert A. Fildes, Ph.D. has been a director since 1991. Since January 1998,
Dr. Fildes has served as President of SB2, Inc., a privately held company
that licenses antibody technology. From June to December 1998,
Dr. Fildes served as Chief Executive Officer of Atlantic Pharmaceuticals,
a publicly held company in the field of biotechnology. From 1993 to 1997,
Dr. Fildes was the Chairman and Chief Executive Officer of Scotgen
Biopharmaceuticals, Inc., a privately held company in the field of human
monoclonal antibody technology. From 1990 to 1993, Dr. Fildes was an
independent consultant in the biopharmaceutical industry. He was the president
and Chief Executive Officer of Cetus Corporation, a publicly held biotechnology
company, from 1982 to 1990. From 1980 to 1982, Dr. Fildes was the
President of Biogen, Inc., which merged with IDEC Pharmaceuticals Corporation
in 2003 to form Biogen Idec, a publicly held biopharmaceutical company, and
from 1975 to 1980, he was the Vice President of Operations for the Industrial
Division of Bristol-Myers Squibb Company. From April 2002 to April 2003,
Dr. Fildes was a director of Polymerat Pty. Ltd. (now Bio-Layer Pty.
Ltd.), a privately held company that develops surfaces for carrying out
biological reactions. Dr. Fildes is currently a director of Inimex
Pharmaceuticals, Inc., a privately held Canadian biotechnology company. Dr.
Fildes holds a D.C.C. degree in Microbial Biochemistry and a Ph.D. in
Biochemical Genetics from the University of London.

|
|
Deirdre Y. Gillespie, M.D.
President and Chief Executive Officer
|
| |
Deirdre Y. Gillespie, M.D., joined the Company in 2006. From 2001 to 2005 she was President and Chief Executive Officer of Oxxon Therapeutics, a privately held pharmaceutical company developing immunotherapies for chronic infectious diseases and cancer. Previously, Dr. Gillespie was Chief Operating Officer at Vical Inc, a publicly-traded gene delivery company focusing on immunotherapeutics and cancer vaccines. Dr Gillespie was also Executive Vice President and Chief Business Officer at Vical. Prior to joining Vical in 1998, she was Vice President Business Development at 3-Dimensional Pharmaceuticals and held senior positions at DuPont Merck Pharmaceutical Company, in both Europe and the United States, including Vice President, Marketing. Prior to completing five years of clinical practice in London and Oxford, Dr. Gillespie spent five years in clinical development with Sandoz Pharma AG (Novartis) in the UK and Switzerland. Dr. Gillespie received her M.B.A. from the London Business School and her M.D., and B.Sc. from London University.

|
|
Stephen M. Martin
Former President, CIBA Vision Corporation; Vice President,Venture
Opportunities, CIBA Vision; Partner, Hi-tech Partners Group;
General Partner, Merritt Capital Services
|
| |
Stephen M. Martin has been a director since April 2000.
Mr. Martin is currently CEO Partner of Hi Tech Partners, LLC, a privately
held consulting firm for executive management of early stage technology
businesses. In April 2009, he joined QSpex Technologies, Inc., an early-stage
private Opthalmic (Spectacle) Lens manufacturing company as Chief Business
Officer. In June 2001, Mr. Martin retired from CIBA Vision
Corporation, a Novartis Company engaged in the research, manufacture and sale
of contact lenses, lens care products and ophthalmic pharmaceuticals.
Mr. Martin founded CIBA Vision in 1980. Mr. Martin was President of
CIBA Vision Corporation, USA from 1995 to 1998 and President of Ciba Vision
Ophthalmics, USA, the company's ophthalmic pharmaceutical division, which he
founded, from 1990 until 1998. He served as CIBA Vision's Vice President of
Venture Opportunities from 1998 until his retirement in 2001. Mr. Martin
currently serves as a director of QSpex Technologies, Inc., a privately held
spectacle manufacturing company, OcuCure Therapeutics, Inc., a privately held
ophthalmic pharmaceutical development company and NeoVista, Inc., a privately
held medical device company. From 2003 to 2005, Mr. Martin served as a
director of Alimera Sciences, Inc., a privately held ophthalmic pharmaceutical
company. Mr. Martin is the inventor on six issued U.S. patents and a number of European patents. Mr. Martin holds a B.A. degree from Wake Forest University and attended the Woodrow Wilson College of Law.

|
|
Frank E. Young, M.D., Ph.D.
Former Commissioner of the United States Food & Drug Administration
|
| |
Frank E. Young, M.D., Ph.D. has been a director since 2005.
Dr. Young is a former Commissioner of the United States Food and Drug
Administration ("FDA") and has had over a 40-year career in medicine, academia
and government. After numerous academic appointments, Dr. Young served as
Chairman of the Department of Microbiology and Professor of Microbiology, of
Pathology, and of Radiation Biology and Biophysics at the University of
Rochester, New York. Subsequently, he became Dean of the School of Medicine and Dentistry, Director of the Medical Center and Vice President for Health Affairs at
the University of Rochester. Dr. Young joined the Department of Health and
Human Services as Commissioner of the FDA and Assistant Surgeon General (Rear
Admiral, USPHS) in 1984. Under Presidents Ronald Reagan, George H.W. Bush, and
William J. Clinton, Dr. Young served as Commissioner of the FDA, Deputy
Assistant Secretary and Director of the Office of Emergency Preparedness,
Director of the National Disaster Medical System and as a member of the
Executive Board of the World Health Organization (presidential appointee).
Dr. Young currently serves as the Chief Executive Officer of Cosmos
Alliance and is a partner of Essex Woodlands Health Ventures. In addition,
Dr. Young currently serves on the board of Golden Pond Healthcare,
publicly held special purpose acquisition company and the boards of the
following private companies: Agennix, Inc. and Elusys Therapeutics, Inc.
Dr. Young attended Union College and holds an M.D. degree from the
University of the State of New York, Upstate Medical Center, where he graduated
cum laude, and a Ph.D. degree from Case Western Reserve University.

|
|
|
|
|
* Copyright © 2000, The Nasdaq Stock Market, Inc. Reprinted
with the permission of The Nasdaq Stock MArket, Inc.
Photo credit: Peter Aaron/Esto
Terms
of Use & Privacy Policy
Copyright © 2008, La Jolla Pharmaceutical Company
|
|
|